Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $90.00 short put and a strike $85.00 long put offers a potential 10.62% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $90.00 by expiration. The full premium credit of $0.48 would be kept by the premium seller. The risk of $4.52 would be incurred if the stock dropped below the $85.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 72.87 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Strong Recon Pushing Stryker’s Rebound
Fri, 18 Oct 2013 15:06:12 GMT
Motley Fool – A rebound in recon and ongoing growth in neuro have pushed Stryker’s shares back to a 52-week high.
Company in great shape: Stryker CEO
Fri, 18 Oct 2013 14:49:00 GMT
CNBC – Stryker CEO Kevin Lobo says his company is in “great shape,” and discusses the gradual increase in people electing to have surgery. He also addresses the hit from recall costs.
Johnson & Johnson Continues To Ride The Success Of Its Immunology And Oncology Drugs
Thu, 17 Oct 2013 22:38:43 GMT
Seeking Alpha – Johnson & Johnson ( JNJ ) posted a moderate growth of 3% in Q3 2013 amid a stable healthcare environment, beating consensus estimates on the back of strong performance from its pharmaceutical business. …
Why Is Johnson & Johnson’s Pharmaceutical Segment Outgrowing Its Other Businesses?
Thu, 17 Oct 2013 18:25:04 GMT
Motley Fool – J&J’s pharmaceuticals business outgrew its other businesses in the third quarter, becoming the company’s core growth driver. What does this mean for the company’s investors?
Danaher Hits New High After Q3 Earnings Beat
Thu, 17 Oct 2013 15:27:00 GMT
Investor’s Business Daily – Danaher Hits New High After Q3 Earnings Beat
Also on Market Tamer…
Follow Us on Facebook